Third Consecutive Double Miss, Revenue 33% Below Consensus Again, Gross Margins Scrape to Zero — But the MVR EPC Is Signed, E15 Is Law, India Is Ramping, and the Only Question Left Is Whether $238M in Debt Maturing April 1 Gets Refinanced Before It Gets Called

Results vs. Consensus

Quality of the Numbers

• Revenue: $59.2M was the best quarter of FY2025, driven by India ramping ($14.5M), higher ethanol pricing ($2.13/gal), and growing RNG volumes. Sequential improvement of 13.4% continues the recovery from Q1's $42.9M trough. But the YoY decline of 27.3% (from $81.4M) and the 33% miss vs. consensus show the business is operating at roughly 65-70% of where the Street expects it to be. The persistent miss is concentrated in India (consensus models $30M+, actual was $14.5M) and the absence of 45Z revenue.
• Gross margins: Essentially breakeven ($-58K gross loss). This is actually an improvement — Q2 was ($3.4M) and Q1 was ($5.1M). The sequential trajectory (Q1: -11.9%, Q2: -6.5%, Q3: ~0%) suggests positive gross margins are achievable in Q4 if India ramps further and LCFS/45Z credits begin flowing. But gross breakeven on $59M in revenue is not a profitable business; it's a business that covers its COGS and nothing else.
• Cash and dilution: Cash improved to $5.6M (from $1.65M), but the source tells the story: $25.5M raised from equity issuance over 9 months, offset by $35.7M in debt repayments and $9.4M in CapEx. The company is funding operations through dilution. Shares grew from 52.6M (Q1) to 63.7M (Q3) — a 21% increase in two quarters. At this rate, the share count reaches 70M+ by year-end.

Quarterly Financial Progression

The financial trajectory is improving on every metric except shares outstanding. Revenue has grown sequentially for three quarters (Q1 $42.9M → Q3 $59.2M, +38%). Gross margins moved from -12% to breakeven. Adj. EBITDA improved from ($13.2M) to ($5.0M). EPS improved from ($0.47) to ($0.37). But the improvement is painfully slow relative to the debt clock, and the share count inflation means per-share metrics are improving partly through dilution math, not operational excellence.

Key Topics & Management Commentary

Overall Management Tone: Optimistic to the point of dissonance. CEO McAfee described the company as "positioned for significant growth in revenues and improved cash flow through year-end and throughout 2026" in a quarter where revenue missed consensus by a third and gross margins were zero. The gap between the forward-looking narrative (MVR, E15, India IPO, 45Z) and the current financial reality (negative equity, massive debt wall, chronic misses) has never been wider. To be fair, the H2 catalysts are real — MVR EPC and E15 are signed and delivered. But the market is pricing survival risk, and management's tone doesn't address it with sufficient urgency.

1. MVR EPC Signed: The Most Important Milestone of the Year

On September 9, Aemetis signed the EPC contract with NPL Construction (a subsidiary of Centuri Holdings) for the $30M Mechanical Vapor Recompression system at the Keyes ethanol plant. This is the highest-conviction near-term catalyst: a known technology, contracted construction partner, $19.7M in grants/tax credits offsetting 66% of the cost, and an estimated $32M/year in incremental cash flow from energy savings, enhanced LCFS credits, and 45Z production credits.

Air permits have not been received as of the earnings date. Construction is targeting Q4 2025 start with Q2 2026 completion.

Assessment: The EPC signing moves MVR from "planned" to "contracted" — the most tangible de-risking event since we initiated coverage. The 66% grant/credit coverage of the $30M cost means the out-of-pocket investment is ~$10M, making the payback on the company's capital less than 4 months at the $32M/yr estimate. The key remaining risk is the air permits: construction can't begin without them, and every month of delay pushes revenue by a month. We model MVR operational in H2 2026 (conservative relative to Q2 2026 target) contributing $15-20M in incremental annual cash flow in its first year (haircut to $32M estimate).

2. E15: California Expands Ethanol Market by 50%

Governor Newsom signed AB30 on October 3, 2025, legalizing 15% ethanol blending in California gasoline. This expands the state's ethanol market by more than 600 million gallons/year — a 50% increase from the current E10 standard. Combined with the EPA's national year-round E15 approval (April 2025), ethanol demand is set for a structural step-up.

Assessment: E15 is a genuine positive for Keyes. At 65 million gallons/year, the plant represents roughly 1% of California's expanded ethanol demand, ensuring full utilization for years. More importantly, the combination of E15 + MVR (lower CI score from 80% natural gas reduction) creates a premium LCFS credit position: lower-CI ethanol benefits more from E15 because it generates more credits per gallon blended. This is a 2026-2027 revenue driver, not a Q3 event, but it fundamentally improves the long-term economics of the Keyes asset.

3. India: Ramping but Still Sub-Scale

India revenue grew 22% QoQ to $14.5M on 12,500 MT at $1,112/MT. Utilization climbed to 33.4% (from 25.2% Q2, 0% Q1). Pricing improved 10% to $1,112/MT. The plant capacity was expanded to 80 million gallons/year at Kakinada. The India IPO was pushed to 2026, with management targeting a $100-300M valuation and a 20-25% minority stake sale. A new CFO with IPO experience was hired during Q3.

Assessment: India is moving in the right direction ($0 → $11.9M → $14.5M) but far slower than the $31M LOIs suggested. At 33% utilization, the plant is generating revenue but likely not operating profit. The IPO push to 2026 is disappointing — this was supposed to generate partial debt repayment funds. At $100-300M valuation and 20-25% stake sale, proceeds of $20-75M could be meaningful for the April 2026 debt wall, but the timing is extremely tight if filings haven't started. We model India at $15-20M/quarter through FY2025-2026, with the IPO as a 2026 event that may or may not arrive in time to help with the April maturity.

4. 45Z: The Dog That Hasn't Barked

Ten months after the 45Z Clean Fuel Production Credit became effective (January 1, 2025), Aemetis has not recognized a single dollar of 45Z revenue. Treasury has not issued final guidance. The DOE GREET model spreadsheet — needed to calculate exact credit amounts — is still pending. Management blamed the delay on "project in-service timing and the government shutdown" and expects monetization to begin in Q4 2025 with quarterly sales thereafter.

"Monetization was delayed by project in-service timing and the government shutdown." — Eric McAfee, CEO

Assessment: 45Z has been the most consistently over-promised, under-delivered element of the thesis for three consecutive quarters. The company is planning a $20M tax credit sale from the September digester completion, which could be meaningful if executed in Q4. But "expects Q4 monetization" has the same credibility as "expects fall 2025 IPO filings" — we've heard it before. We assign 50/50 probability to meaningful 45Z revenue in Q4 2025 and note that the debt refinancing is explicitly contingent on this outcome.

5. Balance Sheet: The Binding Constraint

Total liabilities: $546M. Stockholders' deficit: ($305M). Working capital deficit: ($328M). Cash: $5.6M. Third Eye Capital: ~$238M at 14-21% maturing April 1, 2026. The company raised $25.5M in equity and $29.2M in new borrowing while repaying $35.7M in debt over nine months. Operating cash flow was barely negative ($-2.5M) only because of a $20.3M inventory drawdown and $19.5M in accrued (but unpaid) interest.

Assessment: The accrued interest line ($19.5M) is the most alarming number in the cash flow statement. It means the company is deferring interest payments to Third Eye Capital, which is willing to add it to the balance rather than demand cash. This is a forbearance arrangement in all but name. When Third Eye decides it wants cash (or the debt matures on April 1), the accumulated interest becomes payable. CEO McAfee has a personal guarantee of up to $10M, and all real and personal property is under first-priority liens with cross-default provisions. The refinancing timeline of "H1 2026" must accelerate to prevent a default.

Guidance & Outlook

The next five months determine the thesis. If 45Z is monetized in Q4, Third Eye extends or refinances, and MVR air permits are received for construction start, the company survives and the 2026 story becomes compelling (MVR cash flow + scaled RNG + India ramp + E15 demand). If any of these fail — particularly the debt refinancing — the equity could face restructuring. There is no middle path.

What They're NOT Saying

1. Third Eye Capital forbearance details: $19.5M in accrued unpaid interest over nine months is a de facto forbearance. No disclosure of whether Third Eye has formally agreed to defer cash interest or whether this is simply building up as a payable. The distinction matters: formal forbearance agreements typically come with additional fees and tighter covenants.
2. 45Z revenue quantum: After ten months of credit generation, management has not disclosed even an estimate of accumulated 45Z credits. At $82/MMBtu (McAfee's Q2 estimate) on ~290K MMBtu of 9M 2025 RNG production, the theoretical value is $23.8M. Why hasn't this been disclosed?
3. Refinancing progress: "Targeting H1 2026" with $238M due April 1 means refinancing must close in the next 4-5 months. No disclosure of lender conversations, term sheet progress, or alternative financing plans. The only disclosed sources are 45Z monetization and India IPO proceeds — neither of which has materialized.
4. Dilution trajectory: $25.5M raised from equity in 9 months, growing shares from ~51M to ~64M. No disclosure of remaining ATM capacity, authorized shares, or expected FY2025 ending share count. At the current rate, shares could reach 70M+ by year-end.
5. Going concern language: The 10-Q should address whether the company's ability to continue as a going concern is in doubt given the $328M working capital deficit and $238M in imminent maturities. If the auditor includes a going concern paragraph in the FY2025 10-K, it would trigger additional covenant risks.

Market Reaction

• Pre-earnings close (Nov 5): $2.06
• Earnings day open (Nov 6): $1.64 (-20.4% gap down)
• Nov 6 intraday low: $1.61 (-21.8%)
• Nov 6 close: $1.76 (-14.6%)
• Nov 7 close: $2.10 (+19.3% recovery)
• Volume Nov 6: 2.71M shares (2.6x average)
• Analyst reactions:
  • Stonegate Capital: Initiated coverage at $11.70 median (Nov 14)
  • Ascendiant Capital: Maintained Buy, PT cut $21 → $20.00 (Nov 19)
  • UBS/HC Wainwright: No updates post-Q3

The 20% gap-down followed by a same-week recovery to $2.10 is the AMTX pattern: initial panic on the miss, followed by dip-buying on the catalyst narrative. The stock is now trading almost exclusively on survival probability rather than fundamental value. At $1.76-2.10, the market cap of $112-134M implies the market assigns roughly 20-25% probability that the equity survives the April 2026 debt wall with value. Stonegate's $11.70 target and Ascendiant's $20 PT reflect the value if the company survives; UBS's $3.00 reflects near-term reality.

Street Perspective

Debate: Does the April 2026 Debt Wall Get Refinanced?

Bull view: Third Eye Capital has extended maturities multiple times before — they have no incentive to force liquidation when the underlying assets (Keyes plant, India operations, RNG portfolio, CCS permits, SAF contracts) are worth more as a going concern. The 45Z Treasury guidance is imminent (expected Q4 2025 or Q1 2026), which would demonstrate the recurring cash flow needed to refinance. The India IPO at $100-300M valuation provides a second source. McAfee's personal guarantee of $10M signals skin in the game. Third Eye will extend because the alternative (foreclosure on a complex multi-asset renewable energy company) is worse for them.

Bear view: "Third Eye will extend" is the same logic that has kept bulls in the name for two years while the equity has dropped 80%+ from its highs. At 14-21% interest rates, Third Eye is extracting maximum value from a distressed borrower. If 45Z guidance doesn't come by March 2026, there's no basis for refinancing. The India IPO is untested and pushed back. $25.5M in equity dilution proves the company can't self-fund. At some point, Third Eye forces conversion to equity or triggers a restructuring that wipes out common shareholders.

Our take: We assign 70-75% probability to an extension or refinancing, down from 75-80% last quarter. The direction of the catalysts is right (MVR EPC signed, E15 law, India ramping), but the velocity is insufficient relative to the April timeline. Third Eye's most likely path is a short-term extension (6-12 months) at even higher rates, which keeps the company alive but further burdens the capital structure. A clean refinancing at lower rates requires 45Z monetization, which requires Treasury guidance, which requires federal bureaucracy. We're skeptical that all links in this chain connect by April 1.

Debate: Is $1.76 the Bottom?

Bull view: The stock is at 2-year lows. Every catalyst miss is priced in. If 45Z guidance drops in Q4-Q1, the stock re-rates 50-100% overnight. MVR alone is worth $3-5/share in NPV on a $32M/yr cash flow stream. India IPO could generate $20-75M for debt reduction. The risk/reward is asymmetric at $1.76 for anyone who believes the company survives.

Bear view: The stock has fallen from $3.66 to $1.76 while "catalysts" were supposedly being delivered. Three consecutive double misses. Negative equity. 10% quarterly dilution. $238M due in five months with $5.6M cash. The 52-week low of $1.22 is more relevant than the high. If the April wall isn't resolved, the next stop is equity restructuring and sub-$1.

Our take: The stock is interesting for risk capital below $1.50 and uninvestable above $2.50 under current information. At $1.76-2.10, it's a coin flip on survival. Position sizing, not price targeting, is the only responsible framework.

Model Framework

Valuation: At $1.93 midpoint ($1.76-$2.10 range) / 64M shares, market cap is ~$124M. EV ($124M + $354M debt + $131M preferred - $5.6M cash) is ~$603M. The stock is a survival bet. If the company navigates the April wall and reaches MVR + scaled RNG + India in 2026-2027, fair value is $5-15/share depending on execution. If it doesn't, fair value is $0-0.50.

Thesis Scorecard Post-Earnings

Overall: The thesis is at a crossroads. The operational milestones are being delivered — MVR EPC, E15, India ramp, digester online — but they're arriving too slowly to outrun the debt clock. The balance sheet has worsened every quarter, and the April 2026 maturity wall is now the single variable that determines whether the bull case or bear case prevails. Everything else — revenue trajectory, margins, catalysts, valuation — is secondary to that date.

Action: Maintain Hold at ~$1.93 (midpoint $1.76-$2.10). The operational progress is real but the financial structure cannot absorb another quarter of delay. Upgrade triggers: (1) Third Eye maturity extended or refinanced, (2) 45Z revenue of $10M+ recognized in any quarter, (3) MVR air permits received and construction commences, (4) India at $20M+/quarter for two consecutive quarters. Downgrade to Underperform triggers: (1) Third Eye acceleration or covenant violation, (2) 45Z Treasury guidance unfavorable, (3) going concern opinion in 10-K audit, (4) India reverting to <$10M/quarter.